US Patent

US10420763 — Sublingual apomorphine

Method of Use · Assigned to Sunovion Pharmaceuticals Inc · Expires 2030-06-11 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects sublingual formulations of apomorphine, specifically films or strips containing an acid addition salt of apomorphine and a pH neutralizing agent.

USPTO Abstract

Disclosed are sublingual formulations of apomorphine, and methods of treating Parkinson's disease therewith. The sublingual formulations are films or strips having a first portion comprising apomorphine particles comprising an acid addition salt of apomorphine and a second portion comprising a pH neutralizing agent.

Drugs covered by this patent

apomorphine-hydrochloride (APOMORPHINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2825`	—	apomorphine-hydrochloride
`U-2825`	—	apomorphine-hydrochloride
`U-2825`	—	apomorphine-hydrochloride
`U-2825`	—	apomorphine-hydrochloride
`U-2825`	—	apomorphine-hydrochloride

Patent Metadata

Patent number: US10420763
Jurisdiction: US
Classification: Method of Use
Expires: 2030-06-11
Drug substance claim: No
Drug product claim: Yes
Assignee: Sunovion Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.